Vanguard Group
TERN

Vanguard Group’s Terns Pharmaceuticals TERN Stock Holding History

Vanguard Group’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$223M Buy
5,523,948
+964,031
+21% +$22.3M ﹤0.01% 1494
2025
Q3 		$34.2M Buy
4,559,917
+253,751
+6% +$1.62M ﹤0.01% 2343
2025
Q2 		$16.1M Buy
4,306,166
+154,010
+4% +$481K ﹤0.01% 2656
2025
Q1 		$11.5M Buy
4,152,156
+282,574
+7% +$1.15M ﹤0.01% 2766
2024
Q4 		$21.4M Buy
3,869,582
+512,768
+15% +$3.47M ﹤0.01% 2553
2024
Q3 		$28M Buy
3,356,814
+1,055,872
+46% +$8.69M ﹤0.01% 2431
2024
Q2 		$15.7M Buy
2,300,942
+101,936
+5% +$617K ﹤0.01% 2688
2024
Q1 		$14.4M Buy
2,199,006
+11,535
+0.5% +$75.3K ﹤0.01% 2762
2023
Q4 		$14.2M Sell
2,187,471
-14,643
-0.7% -$77.4K ﹤0.01% 2759
2023
Q3 		$11.1M Sell
2,202,114
-23,157
-1% -$147K ﹤0.01% 2830
2023
Q2 		$19.5M Buy
2,225,271
+934,022
+72% +$10.9M ﹤0.01% 2598
2023
Q1 		$15.3M Buy
1,291,249
+165,213
+15% +$1.58M ﹤0.01% 2721
2022
Q4 		$11.5M Buy
1,126,036
+506,904
+82% +$3.37M ﹤0.01% 2890
2022
Q3 		$3.65M Buy
619,132
+251,603
+68% +$935K ﹤0.01% 3487
2022
Q2 		$912K Sell
367,529
-65,490
-15% -$131K ﹤0.01% 4119
2022
Q1 		$1.29M Sell
433,019
-125,308
-22% -$535K ﹤0.01% 4131
2021
Q4 		$3.95M Buy
558,327
+117,655
+27% +$980K ﹤0.01% 3739
2021
Q3 		$4.59M Buy
440,672
+24,942
+6% +$259K ﹤0.01% 3718
2021
Q2 		$5.1M Sell
415,730
-160,063
-28% -$2.73M ﹤0.01% 3598
2021
Q1 		$12.7M Buy
+575,793
New +$12.6M ﹤0.01% 3023

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CLGM
Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Vanguard Group's TERN Position: Q4 2025 in Review

Vanguard Group increased its Terns Pharmaceuticals (TERN) stake by 21% in Q4 2025, buying an estimated $22.3M and bringing the position to 5,523,948 shares worth $223M. The position accounts for ﹤0.01% of the portfolio, ranked #1494.

Vanguard Group first reported a position in TERN in Q1 2021 and has held it in 20 quarters since. 248 funds tracked by Wall St. Rank hold TERN as of Q4 2025.

  • Vanguard Group held 5,523,948 shares of Terns Pharmaceuticals worth $223M as of Q4 2025.
  • Vanguard Group bought 964,031 Terns Pharmaceuticals shares in Q4 2025, an estimated $22.3M.
  • Terns Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1494 holding.
  • Vanguard Group first reported a position in Terns Pharmaceuticals in Q1 2021 and has held it in 20 quarters since.
  • 248 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.